BI 836826

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BI 836826, covering 2020-07-24 to 2020-11-25. Get the full timeline:

Most recent: Clinical Trial Update: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia [Phase 1]